| Condition |
Trial Name |
Sponsor |
| High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11) |
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan(T-DXd) Monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11) |
AstraZeneca |
| B-Cell Malignancies |
A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies |
InnoCare Pharma Inc. |
| Advanced Hepatocellular Carcinoma |
A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma |
Kintor |
| This is 2L-4L study for patients with R/R MM. |
A Phase III Randomized, open-label trial of SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) in patients with relapsed or Refractory Multiple Myeloma(RRMM). |
EMN 29 |
| First-line HER2-positive Breast Cancer (DESTINY-Breast09). |
A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer (DESTINY-Breast09). |
AstraZeneca |
| Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) |
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) |
Roche |
| Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) |
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) |
Roche-Genetech |
| 2 L and above any Lymphoid Malignancies |
An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients with Lymphoid Malignancies (WWRD Study) |
AVM |
| advanced solid tumors with genomic alterations or protein expression patterns predictive of response |
An Open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response |
Roche-Genetech |
| The first-line treatment of participants with extensive-stage small cell lung cancer |
Phase 3 Study of Chemotherapy with MK-7684A or Atezolizumab in First Line ES-SCLC |
Merck |
| Newly diagnosed diffuse large B-cell lymphoma (DLBCL) |
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL |
MorphoSys AG |
| Advanced/Metastatic Non-small Cell Lung Cancer |
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer |
GSK |
| Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer |
G1 Therapeutics Inc |
